AU2013201584A1 - Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody - Google Patents

Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody Download PDF

Info

Publication number: AU2013201584A1
Authority: AU; Australia
Prior art keywords: additional therapeutic; therapeutic agents; composition; antibody; patient
Prior art date: 2012-03-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2013201584A

Other languages

English (en)

Inventor

Gabriela Garcia

William Kubasek

Gavin Macbeath

Victor Moyo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merrimack Pharmaceuticals Inc

Original Assignee

Merrimack Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-12

Filing date

2013-03-12

Publication date

2013-09-26

2013-03-12 Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc

2013-09-26 Publication of AU2013201584A1 publication Critical patent/AU2013201584A1/en

Status Abandoned legal-status Critical Current

Links

206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 118
201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 111
238000000034 method Methods 0.000 title claims abstract description 101
208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 88
208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 88
238000002648 combination therapy Methods 0.000 title abstract description 23
239000003814 drug Substances 0.000 claims abstract description 163
229940124597 therapeutic agent Drugs 0.000 claims abstract description 150
229960005277 gemcitabine Drugs 0.000 claims abstract description 75
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 74
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 50
239000005551 L01XE03 - Erlotinib Substances 0.000 claims abstract description 48
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims abstract description 48
229960001592 paclitaxel Drugs 0.000 claims abstract description 48
229960001433 erlotinib Drugs 0.000 claims abstract description 47
229960004768 irinotecan Drugs 0.000 claims abstract description 43
108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims abstract description 37
229930012538 Paclitaxel Natural products 0.000 claims abstract description 11
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims abstract 18
238000011282 treatment Methods 0.000 claims description 80
206010028980 Neoplasm Diseases 0.000 claims description 78
239000000203 mixture Substances 0.000 claims description 77
239000003112 inhibitor Substances 0.000 claims description 51
230000004614 tumor growth Effects 0.000 claims description 51
210000004027 cell Anatomy 0.000 claims description 42
125000003275 alpha amino acid group Chemical group 0.000 claims description 32
230000000694 effects Effects 0.000 claims description 27
229940121647 egfr inhibitor Drugs 0.000 claims description 26
239000002777 nucleoside Substances 0.000 claims description 22
150000003833 nucleoside derivatives Chemical class 0.000 claims description 22
239000003795 chemical substances by application Substances 0.000 claims description 21
230000002503 metabolic effect Effects 0.000 claims description 20
229960000303 topotecan Drugs 0.000 claims description 20
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 20
230000000996 additive effect Effects 0.000 claims description 17
230000009467 reduction Effects 0.000 claims description 17
102000029749 Microtubule Human genes 0.000 claims description 16
108091022875 Microtubule Proteins 0.000 claims description 16
101710183280 Topoisomerase Proteins 0.000 claims description 16
201000011510 cancer Diseases 0.000 claims description 16
238000001990 intravenous administration Methods 0.000 claims description 16
210000004688 microtubule Anatomy 0.000 claims description 16
230000035772 mutation Effects 0.000 claims description 16
239000003381 stabilizer Substances 0.000 claims description 16
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 15
102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 15
229960002949 fluorouracil Drugs 0.000 claims description 15
230000004044 response Effects 0.000 claims description 15
230000001225 therapeutic effect Effects 0.000 claims description 15
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 14
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 14
101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 14
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 14
235000008191 folinic acid Nutrition 0.000 claims description 14
239000011672 folinic acid Substances 0.000 claims description 14
229960001691 leucovorin Drugs 0.000 claims description 14
206010061289 metastatic neoplasm Diseases 0.000 claims description 14
MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims description 13
239000002246 antineoplastic agent Substances 0.000 claims description 13
238000011260 co-administration Methods 0.000 claims description 13
229940127089 cytotoxic agent Drugs 0.000 claims description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
229960005167 everolimus Drugs 0.000 claims description 13
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 12
230000002829 reductive effect Effects 0.000 claims description 12
ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 11
230000001394 metastastic effect Effects 0.000 claims description 11
239000000654 additive Substances 0.000 claims description 10
229960001686 afatinib Drugs 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 10
206010069755 K-ras gene mutation Diseases 0.000 claims description 9
208000009956 adenocarcinoma Diseases 0.000 claims description 9
229940124302 mTOR inhibitor Drugs 0.000 claims description 9
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 9
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 9
229960001756 oxaliplatin Drugs 0.000 claims description 9
238000002560 therapeutic procedure Methods 0.000 claims description 9
206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 claims description 8
208000009311 VIPoma Diseases 0.000 claims description 8
238000009175 antibody therapy Methods 0.000 claims description 8
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 8
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 8
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 8
201000000052 gastrinoma Diseases 0.000 claims description 8
238000012447 xenograft mouse model Methods 0.000 claims description 8
229960005395 cetuximab Drugs 0.000 claims description 7
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 7
229960002930 sirolimus Drugs 0.000 claims description 7
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 6
229940127093 camptothecin Drugs 0.000 claims description 6
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 6
238000002512 chemotherapy Methods 0.000 claims description 6
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 6
229910052697 platinum Inorganic materials 0.000 claims description 6
102200055464 rs113488022 Human genes 0.000 claims description 6
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 6
GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 6
239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 5
239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 5
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 5
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 5
229960003668 docetaxel Drugs 0.000 claims description 5
230000002124 endocrine Effects 0.000 claims description 5
229960002584 gefitinib Drugs 0.000 claims description 5
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 5
229960004891 lapatinib Drugs 0.000 claims description 5
BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 5
230000003902 lesion Effects 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
229950008001 matuzumab Drugs 0.000 claims description 5
230000000394 mitotic effect Effects 0.000 claims description 5
229950010203 nimotuzumab Drugs 0.000 claims description 5
229960001972 panitumumab Drugs 0.000 claims description 5
230000000306 recurrent effect Effects 0.000 claims description 5
102200006541 rs121913530 Human genes 0.000 claims description 5
WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical class OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims description 5
239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 5
229960003862 vemurafenib Drugs 0.000 claims description 5
229950008250 zalutumumab Drugs 0.000 claims description 5
HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 claims description 4
XUSKJHCMMWAAHV-SANMLTNESA-N 220913-32-6 Chemical compound C1=C(O)C=C2C([Si](C)(C)C(C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 XUSKJHCMMWAAHV-SANMLTNESA-N 0.000 claims description 4
MYQKIWCVEPUPIL-QFIPXVFZSA-N 7-ethylcamptothecin Chemical compound C1=CC=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 MYQKIWCVEPUPIL-QFIPXVFZSA-N 0.000 claims description 4
FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 claims description 4
BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims description 4
208000009164 Islet Cell Adenoma Diseases 0.000 claims description 4
208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 claims description 4
206010041329 Somatostatinoma Diseases 0.000 claims description 4
201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims description 4
208000006336 acinar cell carcinoma Diseases 0.000 claims description 4
201000008395 adenosquamous carcinoma Diseases 0.000 claims description 4
208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 4
206010022498 insulinoma Diseases 0.000 claims description 4
201000002529 islet cell tumor Diseases 0.000 claims description 4
RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 claims description 4
229950002654 lurtotecan Drugs 0.000 claims description 4
RPFYDENHBPRCTN-NRFANRHFSA-N mdo-cpt Chemical compound C1=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=CC2=C1OCO2 RPFYDENHBPRCTN-NRFANRHFSA-N 0.000 claims description 4
201000011116 pancreatic cholera Diseases 0.000 claims description 4
201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 4
208000021255 pancreatic insulinoma Diseases 0.000 claims description 4
208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims description 4
208000002820 pancreatoblastoma Diseases 0.000 claims description 4
230000002085 persistent effect Effects 0.000 claims description 4
229960001302 ridaforolimus Drugs 0.000 claims description 4
VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims description 4
229950009213 rubitecan Drugs 0.000 claims description 4
208000004548 serous cystadenocarcinoma Diseases 0.000 claims description 4
229960000235 temsirolimus Drugs 0.000 claims description 4
QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 4
229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 4
208000007569 Giant Cell Tumors Diseases 0.000 claims description 3
101150105104 Kras gene Proteins 0.000 claims description 3
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 3
AQSRKNJFNKOMDG-NRFANRHFSA-N ac1lahqt Chemical compound ClC1=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=CC2=C1OCO2 AQSRKNJFNKOMDG-NRFANRHFSA-N 0.000 claims description 3
239000002774 b raf kinase inhibitor Substances 0.000 claims description 3
229960003649 eribulin Drugs 0.000 claims description 3
UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims description 3
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims description 3
208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims description 3
229940108949 paclitaxel injection Drugs 0.000 claims description 3
230000036961 partial effect Effects 0.000 claims description 3
230000001575 pathological effect Effects 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims description 3
241000699660 Mus musculus Species 0.000 claims description 2
229960001573 cabazitaxel Drugs 0.000 claims description 2
BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 2
238000011580 nude mouse model Methods 0.000 claims description 2
102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims 2
101150048834 braF gene Proteins 0.000 claims 2
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
208000002445 cystadenocarcinoma Diseases 0.000 claims 1
229960000255 exemestane Drugs 0.000 claims 1
229950008834 seribantumab Drugs 0.000 description 91
GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 30
238000007912 intraperitoneal administration Methods 0.000 description 26
241000699670 Mus sp. Species 0.000 description 24
101150073133 Cpt1a gene Proteins 0.000 description 14
230000005764 inhibitory process Effects 0.000 description 11
230000004083 survival effect Effects 0.000 description 11
239000000470 constituent Substances 0.000 description 10
210000000496 pancreas Anatomy 0.000 description 10
238000011284 combination treatment Methods 0.000 description 9
229940079593 drug Drugs 0.000 description 7
230000003442 weekly effect Effects 0.000 description 7
102000001301 EGF receptor Human genes 0.000 description 6
108060006698 EGF receptor Proteins 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 6
230000006872 improvement Effects 0.000 description 6
238000001802 infusion Methods 0.000 description 6
210000004072 lung Anatomy 0.000 description 6
238000009097 single-agent therapy Methods 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
206010052747 Adenocarcinoma pancreas Diseases 0.000 description 5
102000038030 PI3Ks Human genes 0.000 description 5
108091007960 PI3Ks Proteins 0.000 description 5
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 5
239000000427 antigen Substances 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
201000002094 pancreatic adenocarcinoma Diseases 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
102100030708 GTPase KRas Human genes 0.000 description 4
101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
102400000058 Neuregulin-1 Human genes 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
239000012634 fragment Substances 0.000 description 4
231100000682 maximum tolerated dose Toxicity 0.000 description 4
238000005259 measurement Methods 0.000 description 4
208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
238000012360 testing method Methods 0.000 description 4
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 3
102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 3
238000011794 NU/NU nude mouse Methods 0.000 description 3
108090000556 Neuregulin-1 Proteins 0.000 description 3
108700020796 Oncogene Proteins 0.000 description 3
229940123237 Taxane Drugs 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000012292 cell migration Effects 0.000 description 3
229960004316 cisplatin Drugs 0.000 description 3
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
238000009826 distribution Methods 0.000 description 3
230000009977 dual effect Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000003384 imaging method Methods 0.000 description 3
229940090044 injection Drugs 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
239000002502 liposome Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
-1 nab-paclitaxel) Chemical compound 0.000 description 3
231100000590 oncogenic Toxicity 0.000 description 3
230000002246 oncogenic effect Effects 0.000 description 3
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 3
238000011295 triple combination therapy Methods 0.000 description 3
LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 2
HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
108060001084 Luciferase Proteins 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
229950002826 canertinib Drugs 0.000 description 2
OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 2
229960004562 carboplatin Drugs 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
230000008859 change Effects 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
OKKDEIYWILRZIA-OSZBKLCCSA-N gemcitabine hydrochloride Chemical compound [H+].[Cl-].O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 OKKDEIYWILRZIA-OSZBKLCCSA-N 0.000 description 2
208000014829 head and neck neoplasm Diseases 0.000 description 2
229940102213 injectable suspension Drugs 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
229960000779 irinotecan hydrochloride Drugs 0.000 description 2
229950009645 istiratumab Drugs 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
229960002502 paclitaxel protein-bound Drugs 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
238000009521 phase II clinical trial Methods 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000011664 signaling Effects 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 description 1
VHZOZCRALQEBDG-UHFFFAOYSA-N (E)-sarcodictyin A Natural products C1=CC2(C)OC1(O)C(C(=O)OC)=CC1C(C(C)C)CC=C(C)C1CC2OC(=O)C=CC1=CN(C)C=N1 VHZOZCRALQEBDG-UHFFFAOYSA-N 0.000 description 1
LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 description 1
KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
SYYMNUFXRFAELA-BTQNPOSSSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol;hydrobromide Chemical compound Br.N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 SYYMNUFXRFAELA-BTQNPOSSSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102100038778 Amphiregulin Human genes 0.000 description 1
108010033760 Amphiregulin Proteins 0.000 description 1
101800001382 Betacellulin Proteins 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010055114 Colon cancer metastatic Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
102100030011 Endoribonuclease Human genes 0.000 description 1
101710199605 Endoribonuclease Proteins 0.000 description 1
102100030323 Epigen Human genes 0.000 description 1
108010016906 Epigen Proteins 0.000 description 1
101800000155 Epiregulin Proteins 0.000 description 1
QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
102000056372 ErbB-3 Receptor Human genes 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
101150099798 GSK1 gene Proteins 0.000 description 1
208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101000871708 Homo sapiens Proheparin-binding EGF-like growth factor Proteins 0.000 description 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
208000007433 Lymphatic Metastasis Diseases 0.000 description 1
239000004425 Makrolon Substances 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
101100381978 Mus musculus Braf gene Proteins 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
KFHMLBXBRCITHF-UHFFFAOYSA-N PD158780 Chemical compound N1=CN=C2C=NC(NC)=CC2=C1NC1=CC=CC(Br)=C1 KFHMLBXBRCITHF-UHFFFAOYSA-N 0.000 description 1
241000158500 Platanus racemosa Species 0.000 description 1
102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
102100029837 Probetacellulin Human genes 0.000 description 1
102100025498 Proepiregulin Human genes 0.000 description 1
102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
229940079156 Proteasome inhibitor Drugs 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
101710183263 Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
108010003723 Single-Domain Antibodies Proteins 0.000 description 1
101150109894 TGFA gene Proteins 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 1
229940028652 abraxane Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229940042992 afinitor Drugs 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940044684 anti-microtubule agent Drugs 0.000 description 1
238000011394 anticancer treatment Methods 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
108010080308 biregulin Proteins 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940088954 camptosar Drugs 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
XFSBPGXNEHXNEG-RZQXXOGCSA-N chembl363206 Chemical compound O([C@H]1C[C@H]2C(C)=CC[C@@H]([C@H]2\C=C(/[C@]2(O)O[C@@]1(C)C=C2)C(=O)OCC)C(C)C)C(=O)\C=C\C1=CN(C)C=N1 XFSBPGXNEHXNEG-RZQXXOGCSA-N 0.000 description 1
238000009104 chemotherapy regimen Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229950006647 cixutumumab Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 1
229960002482 dalotuzumab Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008355 dextrose injection Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
210000000188 diaphragm Anatomy 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
231100000371 dose-limiting toxicity Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
229940071149 erlotinib 100 mg Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
229950008085 figitumumab Drugs 0.000 description 1
IKIBJHWXDSKRKV-UHFFFAOYSA-N fijianolide B Natural products CC1CC(=C)CC(O)C2OC2CC(OC(=O)C=C/CC3OC(C)(CC=C3)C1)C(O)C=CC4CC(=CCO4)C IKIBJHWXDSKRKV-UHFFFAOYSA-N 0.000 description 1
238000009093 first-line therapy Methods 0.000 description 1
150000005699 fluoropyrimidines Chemical class 0.000 description 1
235000013305 food Nutrition 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
229940020967 gemzar Drugs 0.000 description 1
230000001279 glycosylating effect Effects 0.000 description 1
235000019410 glycyrrhizin Nutrition 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000003128 head Anatomy 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
108010044853 histidine-rich proteins Proteins 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
MSBQEQDLFWWWMV-XZZGLLCESA-N laulimalide Chemical compound C(/[C@H](O)[C@H]1OC(=O)\C=C/C[C@@H]2C=CC[C@H](O2)C[C@H](CC(=C)C[C@H](O)[C@@H]2O[C@H]2C1)C)=C\[C@@H]1CC(C)=CCO1 MSBQEQDLFWWWMV-XZZGLLCESA-N 0.000 description 1
229940008678 levoleucovorin Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
201000000014 lung giant cell carcinoma Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
201000011519 neuroendocrine tumor Diseases 0.000 description 1
150000007523 nucleic acids Chemical group 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000011518 platinum-based chemotherapy Methods 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229950009876 poziotinib Drugs 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
239000003207 proteasome inhibitor Substances 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 description 1
XFSBPGXNEHXNEG-UHFFFAOYSA-N sarcodictyin B Natural products C1=CC2(C)OC1(O)C(C(=O)OCC)=CC1C(C(C)C)CC=C(C)C1CC2OC(=O)C=CC1=CN(C)C=N1 XFSBPGXNEHXNEG-UHFFFAOYSA-N 0.000 description 1
VHZOZCRALQEBDG-BEMXCNERSA-N sarcodictyin a Chemical compound O([C@H]1C[C@H]2C(C)=CC[C@@H]([C@H]2\C=C(/[C@]2(O)O[C@@]1(C)C=C2)C(=O)OC)C(C)C)C(=O)\C=C\C1=CN(C)C=N1 VHZOZCRALQEBDG-BEMXCNERSA-N 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000011519 second-line treatment Methods 0.000 description 1
CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
229950010746 selumetinib Drugs 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
238000011125 single therapy Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940120982 tarceva Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229940100411 torisel Drugs 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229940034727 zelboraf Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2013201584A 2012-03-12 2013-03-12 Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody Abandoned AU2013201584A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261609696P	2012-03-12	2012-03-12
US61/609,696		2012-03-12
PCT/US2013/030585 WO2013138371A1 (fr)	2012-03-12	2013-03-12	Procédés de traitement du cancer du pancréas à l'aide de thérapies combinées comprenant un anticorps anti-erbb3

Publications (1)

Publication Number	Publication Date
AU2013201584A1 true AU2013201584A1 (en)	2013-09-26

Family

ID=49161736

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2013201584A Abandoned AU2013201584A1 (en)	2012-03-12	2013-03-12	Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody

Country Status (2)

Country	Link
AU (1)	AU2013201584A1 (fr)
WO (1)	WO2013138371A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107205979A (zh) *	2014-12-02	2017-09-26	细胞基因公司	组合疗法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8691231B2 (en)	2011-06-03	2014-04-08	Merrimack Pharmaceuticals, Inc.	Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
AU2013202947B2 (en) *	2012-06-13	2016-06-02	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en)	2012-06-13	2017-08-01	Ipsen Biopharm Ltd.	Methods for treating pancreatic cancer using combination therapies
US20140199405A1 (en) *	2013-01-11	2014-07-17	Abraxis Bioscience, Llc	Method for treating cancer based on mutation status of k-ras
MA39599A (fr)	2014-05-14	2016-10-05	Merrimack Pharmaceuticals Inc	Dosage et administration d'agents thérapeutiques anti-egfr
HK1248539A1 (zh)	2015-04-17	2018-10-19	梅里麦克制药股份有限公司	借助塞里班土单抗的组合治疗
US11318131B2 (en)	2015-05-18	2022-05-03	Ipsen Biopharm Ltd.	Nanoliposomal irinotecan for use in treating small cell lung cancer
US20180221478A1 (en) *	2015-07-27	2018-08-09	Innocimab Pte Ltd	Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using using monoclonal antibodies against the epidermal growth factor receptor (egfr)
HK1257216A1 (zh)	2015-08-20	2019-10-18	益普生生物制药有限公司	使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法
BR112018002941B1 (pt)	2015-08-21	2023-12-05	Ipsen Biopharm Ltd	Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
WO2017070456A1 (fr) *	2015-10-22	2017-04-27	Merrimack Pharmaceuticals, Inc.	Méthodes de traitement du cancer par l'administration d'un anticorps bispécifique antagoniste d'igf-ir et d'erbb3 et une combinaison d'anticorps anti-egfr
KR102456433B1 (ko)	2016-03-02	2022-10-19	에자이 알앤드디 매니지먼트 가부시키가이샤	에리불린-기반 항체-약물 콘주게이트 및 사용 방법
AU2017235450A1 (en)	2016-03-15	2018-08-16	Merrimack Pharmaceuticals, Inc.	Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
CN110402163A (zh)	2016-11-02	2019-11-01	易普森生物制药有限公司	使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
WO2018134254A1 (fr)	2017-01-17	2018-07-26	Heparegenix Gmbh	Inhibiteurs de protéine kinase pour favoriser la régénération du foie, ou pour réduire ou prévenir la mort des hépatocytes
JP7660595B2 (ja)	2020-05-27	2025-04-11	コーセプトセラピューティクス，インコーポレイテッド	Ｃｙｐ２ｃ８及びｃｙｐ３ａ４の二重基質、糖質コルチコイド・レセプター・モジュレーターのリラコリラント及びパクリタキセルの併用投与

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110008327A1 (en) *	2004-03-29	2011-01-13	Cheng Jin Q	Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
HRP20131113T1 (hr) *	2007-02-16	2014-01-17	Merrimack Pharmaceuticals, Inc.	Protutijela protiv erbb3 i njihova uporaba

2013
- 2013-03-12 AU AU2013201584A patent/AU2013201584A1/en not_active Abandoned
- 2013-03-12 WO PCT/US2013/030585 patent/WO2013138371A1/fr not_active Ceased

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107205979A (zh) *	2014-12-02	2017-09-26	细胞基因公司	组合疗法

Also Published As

Publication number	Publication date
WO2013138371A1 (fr)	2013-09-19

Publication	Publication Date	Title
AU2013201584A1 (en)	2013-09-26	Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
US20220324979A1 (en)	2022-10-13	Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
US10695426B2 (en)	2020-06-30	Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
EP3035964B1 (fr)	2020-09-23	Traitement du cancer avec une combinaison d'un antagoniste de pd-1 et du dinaciclib
AU2015384801B2 (en)	2022-01-06	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP2882454B1 (fr)	2018-10-10	Polythérapie pour le traitement d'un glioblastome
US20150231238A1 (en)	2015-08-20	Overcoming resistance to erbb pathway inhibitors
KR20170137717A (ko)	2017-12-13	암의 치료를 위한 방법, 조성물, 및 키트
CA2860941C (fr)	2019-11-05	Polytherapie pour le traitement d'un cancer de l'ovaire
WO2013023043A2 (fr)	2013-02-14	Traitement de tumeurs solides avancées à l'aide d'une combinaison d'une immunothérapie anti-erbb3 et d'une chimiothérapie sélectionnée
AU2018389196A1 (en)	2020-06-11	Methods and combination therapy to treat cancer
JP2019517507A (ja)	2019-06-24	特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
EP3976090A1 (fr)	2022-04-06	Polythérapies faisant appel à des inhibiteurs de cdk
KR20210025064A (ko)	2021-03-08	항-her1, her2 또는 her4 항체와 포지오티닙의 조합물 및 이의 사용 방법
HK40010365B (en)	2021-12-17	Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
HK40010365A (en)	2020-07-03	Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer

Legal Events

Date	Code	Title	Description
2016-02-04	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted

AU2013201584A1 - Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=49161736

Family Applications (1)

Country Status (2)

Cited By (1)

Families Citing this family (16)

Family Cites Families (2)

Cited By (1)

Also Published As

Similar Documents

Legal Events